Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lazzari, Chiara, Pecciarini, Lorenza, Doglioni, Claudio, Pedica, Federica, Gajate, Ana Maria Samanes, Bulotta, Alessandra, Gregorc, Vanesa, Cangi, Maria Giulia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676932/
https://www.ncbi.nlm.nih.gov/pubmed/36419889
http://dx.doi.org/10.3389/fonc.2022.1038774
_version_ 1784833700293246976
author Lazzari, Chiara
Pecciarini, Lorenza
Doglioni, Claudio
Pedica, Federica
Gajate, Ana Maria Samanes
Bulotta, Alessandra
Gregorc, Vanesa
Cangi, Maria Giulia
author_facet Lazzari, Chiara
Pecciarini, Lorenza
Doglioni, Claudio
Pedica, Federica
Gajate, Ana Maria Samanes
Bulotta, Alessandra
Gregorc, Vanesa
Cangi, Maria Giulia
author_sort Lazzari, Chiara
collection PubMed
description Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib.
format Online
Article
Text
id pubmed-9676932
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96769322022-11-22 Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib Lazzari, Chiara Pecciarini, Lorenza Doglioni, Claudio Pedica, Federica Gajate, Ana Maria Samanes Bulotta, Alessandra Gregorc, Vanesa Cangi, Maria Giulia Front Oncol Oncology Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors. Larotrectinib and entrectinib have been the first tumor-agnostic compounds approved for the treatment of NTRK fusion-positive tumors. Here, we report the first case of a female patient with a diagnosis of stage IV lung adenocarcinoma harboring the EML4::NTRK3 gene fusion, and successfully treated with entrectinib. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676932/ /pubmed/36419889 http://dx.doi.org/10.3389/fonc.2022.1038774 Text en Copyright © 2022 Lazzari, Pecciarini, Doglioni, Pedica, Gajate, Bulotta, Gregorc and Cangi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lazzari, Chiara
Pecciarini, Lorenza
Doglioni, Claudio
Pedica, Federica
Gajate, Ana Maria Samanes
Bulotta, Alessandra
Gregorc, Vanesa
Cangi, Maria Giulia
Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title_full Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title_fullStr Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title_full_unstemmed Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title_short Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
title_sort case report: eml4::ntrk3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676932/
https://www.ncbi.nlm.nih.gov/pubmed/36419889
http://dx.doi.org/10.3389/fonc.2022.1038774
work_keys_str_mv AT lazzarichiara casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT pecciarinilorenza casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT doglioniclaudio casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT pedicafederica casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT gajateanamariasamanes casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT bulottaalessandra casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT gregorcvanesa casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib
AT cangimariagiulia casereporteml4ntrk3genefusioninapatientwithmetastaticlungadenocarcinomasuccessfullytreatedwithentrectinib

Ejemplares similares